Published in Cancer Res on March 23, 2010
4-Methylumbelliferone as a Treatment for Chronic HBV/HCV | NCT00225537
Hyaluronan synthase HAS2 promotes tumor progression in bone by stimulating the interaction of breast cancer stem-like cells with macrophages and stromal cells. Cancer Res (2011) 1.20
Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis. Cancer (2010) 1.18
Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discov (2011) 1.17
Targeting hyaluronidase for cancer therapy: antitumor activity of sulfated hyaluronic acid in prostate cancer cells. Cancer Res (2011) 1.15
Inhibition of oesophageal squamous cell carcinoma progression by in vivo targeting of hyaluronan synthesis. Mol Cancer (2011) 1.06
Inhibition of hyaluronan retention by 4-methylumbelliferone suppresses osteosarcoma cells in vitro and lung metastasis in vivo. Br J Cancer (2011) 0.99
Targeting hyaluronic acid family for cancer chemoprevention and therapy. Adv Cancer Res (2014) 0.96
4-methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer. Front Immunol (2015) 0.95
C-X-C chemokine receptor 7: a functionally associated molecular marker for bladder cancer. Cancer (2012) 0.93
Dietary supplement 4-methylumbelliferone: an effective chemopreventive and therapeutic agent for prostate cancer. J Natl Cancer Inst (2015) 0.92
The Role of CD44 in Disease Pathophysiology and Targeted Treatment. Front Immunol (2015) 0.91
Molecular characterization of kidney cancer: association of hyaluronic acid family with histological subtypes and metastasis. Cancer (2011) 0.88
Inhibition of hyaluronan synthase-3 decreases subcutaneous colon cancer growth by increasing apoptosis. Anticancer Agents Med Chem (2011) 0.88
Glycosaminoglycans and glucose prevent apoptosis in 4-methylumbelliferone-treated human aortic smooth muscle cells. J Biol Chem (2011) 0.88
Hyaluronan, Inflammation, and Breast Cancer Progression. Front Immunol (2015) 0.87
The roles of hyaluronan/RHAMM/CD44 and their respective interactions along the insidious pathways of fibrosarcoma progression. Biomed Res Int (2013) 0.87
CD44 and RHAMM are essential for rapid growth of bladder cancer driven by loss of Glycogen Debranching Enzyme (AGL). BMC Cancer (2016) 0.86
The hyaluronan synthesis inhibitor 4-methylumbelliferone exhibits antitumor effects against mesenchymal-like canine mammary tumor cells. Oncol Lett (2013) 0.85
Hyaluronan synthase 2 protects skin fibroblasts against apoptosis induced by environmental stress. J Biol Chem (2014) 0.84
Modulation of root branching by a coumarin derivative. Plant Signal Behav (2011) 0.84
Hyaluronan stimulates pancreatic cancer cell motility. Oncotarget (2016) 0.83
4-Methylumbelliferone inhibits ovarian cancer growth by suppressing thymidine phosphorylase expression. J Ovarian Res (2014) 0.83
Reduced chondrogenic matrix accumulation by 4-methylumbelliferone reveals the potential for selective targeting of UDP-glucose dehydrogenase. Matrix Biol (2011) 0.82
Treatment with the hyaluronic Acid synthesis inhibitor 4-methylumbelliferone suppresses LPS-induced lung inflammation. Inflammation (2015) 0.81
Hyaluronan synthesis inhibitor supplements the inhibitory effects of zoledronic acid on bone metastasis of lung cancer. Clin Exp Metastasis (2013) 0.80
Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma. J Urol (2012) 0.80
Isothiocyanate analogs targeting CD44 receptor as an effective strategy against colon cancer. Med Chem Res (2014) 0.80
Modulation of extracellular matrix in cancer is associated with enhanced tumor cell targeting by bacteriophage vectors. Mol Cancer (2015) 0.78
Improving the distribution of Doxil® in the tumor matrix by depletion of tumor hyaluronan. J Control Release (2014) 0.78
The Role of CD44 in Glucose Metabolism in Prostatic Small Cell Neuroendocrine Carcinoma. Mol Cancer Res (2016) 0.77
Antitumor effects of the hyaluronan inhibitor 4-methylumbelliferone on pancreatic cancer. Oncol Lett (2016) 0.77
Synthesis of N-acetyl Glucosamine Analogs as Inhibitors for Hyaluronan Biosynthesis. J Carbohydr Chem (2013) 0.77
Effects of 4-methylumbelliferone and high molecular weight hyaluronic acid on the inflammation of corneal stromal cells induced by LPS. Graefes Arch Clin Exp Ophthalmol (2016) 0.76
Utilization of Glycosaminoglycans/Proteoglycans as Carriers for Targeted Therapy Delivery. Int J Cell Biol (2015) 0.76
Identification, design and synthesis of tubulin-derived peptides as novel hyaluronan mimetic ligands for the receptor for hyaluronan-mediated motility (RHAMM/HMMR). Integr Biol (Camb) (2015) 0.76
4-Methylumbelliferone Suppresses Hyaluronan Synthesis and Tumor Progression in SCID Mice Intra-abdominally Inoculated With Pancreatic Cancer Cells. Pancreas (2016) 0.76
Tumor Microenvironment Remodeling by 4-Methylumbelliferone Boosts the Antitumor Effect of Combined Immunotherapy in Murine Colorectal Carcinoma. Mol Ther (2015) 0.75
Hyaluronic acid synthesis is required for zebrafish tail fin regeneration. PLoS One (2017) 0.75
The Development of a Novel Therapeutic Strategy to Target Hyaluronan in the Extracellular Matrix of Pancreatic Ductal Adenocarcinoma. Int J Mol Sci (2017) 0.75
The 2016 John J. Abel Award Lecture: Targeting the Mechanical Microenvironment in Cancer. Mol Pharmacol (2016) 0.75
Synergistic effect of targeting the epidermal growth factor receptor and hyaluronan synthesis in oesophageal squamous cell carcinoma cells. Br J Pharmacol (2015) 0.75
4-Methylumbelliferone Diminishes Catabolically Activated Articular Chondrocytes and Cartilage Explants via a Mechanism Independent of Hyaluronan Inhibition. J Biol Chem (2016) 0.75
Anti-tumor and anti-invasion effects of a combination of 4-methylumbelliferone and ionizing radiation in human fibrosarcoma cells. Oncol Lett (2016) 0.75
Human serum-derived protein removes the need for coating in defined human pluripotent stem cell culture. Nat Commun (2016) 0.75
The hyaluronic acid inhibitor 4-methylumbelliferone is an NSMase2 activator-role of Ceramide in MU anti-tumor activity. Biochim Biophys Acta (2015) 0.75
Hyaluronan Does Not Regulate Human Epidermal Keratinocyte Proliferation and Differentiation. J Biol Chem (2015) 0.75
Inhibition of Hyaluronic Acid Synthesis Suppresses Angiogenesis in Developing Endometriotic Lesions. PLoS One (2016) 0.75
Over expression of hyaluronan promotes progression of HCC via CD44-mediated pyruvate kinase M2 nuclear translocation. Am J Cancer Res (2016) 0.75
Involvement of glycogen debranching enzyme in bladder cancer. Biomed Rep (2017) 0.75
4-methylumbelliferone and imatinib combination enhances senescence induction in chronic myeloid leukemia cell lines. Invest New Drugs (2016) 0.75
The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem (2007) 3.38
Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J Biol Chem (1999) 3.34
Hyaluronic acid and HYAL-1 in prostate biopsy specimens: predictors of biochemical recurrence. J Urol (2009) 2.36
Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res (2007) 2.12
HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor. Cancer Res (2005) 1.77
Abnormal accumulation of hyaluronan matrix diminishes contact inhibition of cell growth and promotes cell migration. Proc Natl Acad Sci U S A (2002) 1.76
Spontaneous metastasis of prostate cancer is promoted by excess hyaluronan synthesis and processing. Am J Pathol (2009) 1.63
Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells. J Biol Chem (2005) 1.60
A novel mechanism for the inhibition of hyaluronan biosynthesis by 4-methylumbelliferone. J Biol Chem (2004) 1.60
4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3. Exp Cell Res (2009) 1.59
Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J Biol Chem (2001) 1.58
Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44. Cancer Res (2008) 1.48
Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. J Biol Chem (2006) 1.41
Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice. Am J Pathol (2002) 1.36
HYAL1 hyaluronidase: a molecular determinant of bladder tumor growth and invasion. Cancer Res (2005) 1.36
Silencing of hyaluronan synthase 2 suppresses the malignant phenotype of invasive breast cancer cells. Int J Cancer (2007) 1.35
Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer. Int J Cancer (2004) 1.34
Selective expression and functional characteristics of three mammalian hyaluronan synthases in oncogenic malignant transformation. J Biol Chem (2004) 1.33
A hyaluronan synthase suppressor, 4-methylumbelliferone, inhibits liver metastasis of melanoma cells. FEBS Lett (2005) 1.31
Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer. Cancer Res (1997) 1.28
Role, metabolism, chemical modifications and applications of hyaluronan. Curr Med Chem (2009) 1.26
Hyaluronan and hyaluronidase in genitourinary tumors. Front Biosci (2008) 1.24
Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells. Mol Cancer (2007) 1.24
Low molecular weight hyaluronan from stretched lung enhances interleukin-8 expression. Am J Respir Cell Mol Biol (2003) 1.23
Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer. Cancer Res (2003) 1.22
The role of caveolin-1 in prostate cancer: clinical implications. Prostate Cancer Prostatic Dis (2009) 1.20
Hyaluronan fragments induce cytokine and metalloprotease upregulation in human melanoma cells in part by signalling via TLR4. Exp Dermatol (2007) 1.17
Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate (2003) 1.13
Strong Stromal Hyaluronan Expression Is Associated with PSA Recurrence in Local Prostate Cancer. Urol Int (2002) 1.12
Inducible hyaluronan production reveals differential effects on prostate tumor cell growth and tumor angiogenesis. J Biol Chem (2007) 1.11
Hyaluronan-based polymer scaffold modulates the expression of inflammatory and degradative factors in mesenchymal stem cells: Involvement of Cd44 and Cd54. J Cell Physiol (2006) 1.09
Altered hyaluronan biosynthesis in cancer progression. Semin Cancer Biol (2008) 1.09
Hyaluronan induces vascular smooth muscle cell migration through RHAMM-mediated PI3K-dependent Rac activation. Cardiovasc Res (2006) 1.04
Induction and reversal of cell adhesion-dependent multicellular drug resistance in solid breast tumors. Hum Cell (1996) 1.02
The hyaluronan synthesis inhibitor 4-methylumbelliferone prevents keratinocyte activation and epidermal hyperproliferation induced by epidermal growth factor. J Invest Dermatol (2004) 0.98
Functional proteomic screen identifies a modulating role for CD44 in death receptor-mediated apoptosis. Cancer Res (2005) 0.95
Expression of CD44 in prostate cancer cells: association with cell proliferation and invasive potential. Anticancer Res (1995) 0.95
Effect of a hyaluronan synthase suppressor, 4-methylumbelliferone, on B16F-10 melanoma cell adhesion and locomotion. Biochem Biophys Res Commun (2004) 0.94
Study of hyaluronan synthase inhibitor, 4-methylumbelliferone derivatives on human pancreatic cancer cell (KP1-NL). Biochem Biophys Res Commun (2006) 0.93
Sensitization of human K562 leukemic cells to TRAIL-induced apoptosis by inhibiting the DNA-PKcs/Akt-mediated cell survival pathway. Biochem Pharmacol (2009) 0.91
Increased invasion and expression of MMP-9 in human colorectal cell lines by a CD44-dependent mechanism. Anticancer Res (2004) 0.91
Epigenetic regulation of HYAL-1 hyaluronidase expression. identification of HYAL-1 promoter. J Biol Chem (2008) 0.91
Effect of coumarin on the normal rat prostate and on the R-3327H prostatic adenocarcinoma. Cancer Res (1989) 0.86
Inhibition of hyaluronan synthesis in Streptococcus equi FM100 by 4-methylumbelliferone. Eur J Biochem (2002) 0.86
HYAL1-v1, an alternatively spliced variant of HYAL1 hyaluronidase: a negative regulator of bladder cancer. Cancer Res (2006) 0.85
Hyaluronan fragments induce the synthesis of MCP-1 and IL-8 in cultured human peritoneal mesothelial cells. Cell Tissue Res (2001) 0.83
NF-kappa B activation mediates the cross-talk between extracellular matrix and interferon-gamma (IFN-gamma) leading to enhanced monokine induced by IFN-gamma (MIG) expression in macrophages. J Biol Chem (2002) 0.82
Surface-dependent modulation of proliferation, bone matrix molecules, and inflammatory factors in human osteoblasts. J Biomed Mater Res A (2009) 0.81
Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models. Int J Cancer (2009) 0.79
Renal carcinoma with supradiaphragmatic tumor thrombus: avoiding sternotomy and cardiopulmonary bypass. Ann Thorac Surg (2010) 2.51
Contemporary open ureteral reimplantation without morphine: assessment of pain and outcomes. J Urol (2009) 1.41
Modified surgical technique for the management of renal cell carcinoma with level I or II tumor thrombus. Urology (2012) 1.40
Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. J Clin Invest (2013) 1.24
Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis. Cancer (2010) 1.18
Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis. Chem Biol Interact (2008) 1.16
Targeting hyaluronidase for cancer therapy: antitumor activity of sulfated hyaluronic acid in prostate cancer cells. Cancer Res (2011) 1.15
Depressed mood in class III obesity predicted by weight-related stigma. Obes Surg (2007) 1.06
Liver transplantation techniques for the surgical management of renal cell carcinoma with tumor thrombus in the inferior vena cava: step-by-step description. Eur Urol (2010) 1.04
Host innate recognition of an intestinal bacterial pathogen induces TRIF-dependent protective immunity. J Exp Med (2011) 1.02
CXC receptor-1 silencing inhibits androgen-independent prostate cancer. Cancer Res (2009) 1.00
Pre-surgery binge eating status: effect on eating behavior and weight outcome after gastric bypass. Obes Surg (2006) 0.95
Chemokine and chemokine receptor expression in kidney tumors: molecular profiling of histological subtypes and association with metastasis. J Urol (2012) 0.94
C-X-C chemokine receptor 7: a functionally associated molecular marker for bladder cancer. Cancer (2012) 0.93
Epigenetic regulation of HYAL-1 hyaluronidase expression. identification of HYAL-1 promoter. J Biol Chem (2008) 0.91
Emotional eating in a morbidly obese bariatric surgery-seeking population. Obes Surg (2007) 0.91
Cell adhesive affinity does not dictate primitive endoderm segregation and positioning during murine embryoid body formation. Genesis (2009) 0.91
Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients. BJU Int (2012) 0.90
Molecular characterization of kidney cancer: association of hyaluronic acid family with histological subtypes and metastasis. Cancer (2011) 0.88
Galectin-3 expression in prostate cancer and benign prostate tissues: correlation with biochemical recurrence. World J Urol (2012) 0.83
Genistein enhances the efficacy of cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer cells. Prostate (2013) 0.80
Achyranthes aspera (Apamarg) leaf extract inhibits human pancreatic tumor growth in athymic mice by apoptosis. J Ethnopharmacol (2012) 0.80
Salvage robot-assisted partial nephrectomy for the management of renal cell carcinoma following failed stereotactic radiotherapy. JSLS (2012) 0.78
Editorial comment to nomograms to predict the pathological stage of clinically localized prostate cancer in Korean men: comparison with western predictive tools using decision curve analysis. Int J Urol (2012) 0.77
Intravesical methylene blue facilitates precise identification of the diverticular neck during robot-assisted laparoscopic bladder diverticulectomy. J Laparoendosc Adv Surg Tech A (2012) 0.77
Partial sampling of radical prostatectomy specimens: detection of positive margins and extraprostatic extension. Am J Surg Pathol (2013) 0.77
Prognostic implications of partial sampling of radical prostatectomy specimens: comparison of 3 methods. J Urol (2012) 0.76
Surgical technique of removal of inferior vena cava leiomyosarcoma extending into the right atrium without deep hypothermic circulatory arrest. J Card Surg (2010) 0.76
Techniques for avoidance of sternotomy and cardiopulmonary bypass during resection of extensive renal cell carcinoma with vena caval tumor thrombus extension above the diaphragm. J Card Surg (2009) 0.75
Analysis of supraglottic activity during vocalization in healthy singers. Laryngoscope (2013) 0.75
En bloc mobilization of the spleen, pancreas, and colon during hand-assisted laparoscopic left donor nephrectomy. Eur Urol (2011) 0.75
Cardiopulmonary bypass and renal cell carcinoma with level iv tumour thrombus: can deep hypothermic circulatory arrest limit perioperative mortality? BJU Int (2010) 0.75
Surgical resection of a virilizing adrenal mass with extensive tumor thrombus. Can J Urol (2011) 0.75